title: Anti-/pro-apoptotic effects of hesperetin against 7,12-dimetylbenz(a)anthracene-induced alteration in animals.
abstract: This study investigated the anticancer effects of hesperetin on 7,12-dimethylbenz(a)anthracene (DMBA)-treated animals and explored its anticancer mechanism. The experiment consisted of two parts. First, Sprague-Dawley rats were given hesperetin daily at a dose of 50 mg/kg for 8 weeks after a single dose of DMBA (100 mg/kg). As controls, rats were divided into vehicle alone and DMBA alone groups. Secondly, ICR mice were given hesperetin daily at a dose of 10 and 50 mg/kg BW/day for 7 weeks before a single dose of DMBA (34 mg/kg/week). In rats with DMBA-induced mammary gland tumors, hesperetin pretreatment significantly reduced the tumor burden and PCNA overexpression. The administration of hesperetin significantly inhibited mammary gland carcinoma from developing by restoring the decreased Bcl-2 and increased Bax expression. By contrast, in the livers of mice treated with DMBA, obvious DNA fragmentation was observed. Moreover, apoptosis-related gene expression in the livers of the mice differed from that in mammary gland carcinomas in rats. These changes were restored in mice treated with hesperetin, indicating the inhibition of apoptosis. Based on these results, hesperetin may act not only as a proapoptotic agent, but also as an antiapoptotic agent, depending on the circumstance.
authors.affiliation: Plant Resources Research Institute, Duksung Women's University, 419 Ssangmun-dong, Tobong-ku, Seoul 132-714, Republic of Korea. ejchoi@duksung.ac.kr
authors.forename: Eun Jeong
authors.initials: EJ
authors.lastname: Choi
authors.forename: Gun-Hee
authors.initials: GH
authors.lastname: Kim
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D002277:Carcinoma / Q000139:chemically induced / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D005260:Female; D006569:Hesperidin / Q000008:administration & dosage / Q000494:pharmacology*; D015674:Mammary Neoplasms, Animal / Q000139:chemically induced / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008813:Mice, Inbred ICR; D051381:Rats; D017207:Rats, Sprague-Dawley; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D015127:9,10-Dimethyl-1,2-benzanthracene; D006569:Hesperidin; C013015:hesperetin